BioNTech SE (FRA:22UA)
80.00
+1.00 (1.27%)
At close: Dec 19, 2025
BioNTech SE Revenue
BioNTech SE had revenue of 1.52B EUR in the quarter ending September 30, 2025, with 22.02% growth. This brings the company's revenue in the last twelve months to 3.15B, up 3.70% year-over-year. In the year 2024, BioNTech SE had annual revenue of 2.75B, down -27.96%.
Revenue (ttm)
3.15B
Revenue Growth
+3.70%
P/S Ratio
6.02
Revenue / Employee
465.52K
Employees
6,772
Market Cap
18.98B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.75B | -1.07B | -27.96% |
| Dec 31, 2023 | 3.82B | -13.49B | -77.94% |
| Dec 31, 2022 | 17.31B | -1.67B | -8.78% |
| Dec 31, 2021 | 18.98B | 18.49B | 3,834.63% |
| Dec 31, 2020 | 482.30M | 373.70M | 344.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 45.87B |
| Siemens Healthineers AG | 23.38B |
| Fresenius SE & Co. KGaA | 22.45B |
| Merck KGaA | 21.27B |
| Fresenius Medical Care AG | 19.64B |
| Sartorius Aktiengesellschaft | 3.52B |
| Redcare Pharmacy NV | 2.82B |
| Fielmann Group AG | 2.42B |
BioNTech SE News
- 5 days ago - Noteworthy ETF Inflows: FNDF, APTV, BNTX, NXPI - Nasdaq
- 12 days ago - BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart - Seeking Alpha
- 12 days ago - BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options - Benzinga
- 12 days ago - BioNTech, Bristol-Myers Squibb Announce Interim Results From Pumitamig Study - Nasdaq
- 13 days ago - BioNTech SE: BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer - Finanz Nachrichten
- 13 days ago - BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer - GlobeNewsWire
- 14 days ago - BioNTech (BNTX) Sees Promising Survival Data in Lung Cancer Trial - GuruFocus
- 15 days ago - BioNTech SE: BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer - Finanz Nachrichten